Monday, September 17, 2018 Daily Archives

BIA Separations opens upstream lab; looks to future expansions

The newly opened lab looks to optimize the interface between upstream and downstream processing, says Slovenian bioprocessing firm BIA Separations. Developed on the back of customer demand, the upstream processing laboratory aims to optimize the critical interface between upstream and downstream processing for the production of complex molecules and biologics. BIA Separation CEO Aleš Štrancar said that product-contaminant complexes formed during upstream production represent a consistent and challenging obstacle for downstream processing. “These complexes interfere with every aspect of bioprocessing…

B-I working with CMO on viral therapies after $245m ViraTherapeutics buy

Boehringer Ingelheim has acquired ViraTherapeutics for €210 million ($245 million) and tells us how it will integrate the viral therapy firm into its oncology business. In September 2016, German biomanufacturer Boehringer Ingelheim partnered with Austrian based ViraTherapeutics GmbH to develop an oncolytic virus therapy platform and bring various programs through the clinic. As part of the deal, Boehringer Ingelheim had the right to acquire its collaborator after the conclusion of Phase I clinical development, something the firm has now undertaken…